Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors.
Peccatori J, Forcina A, Clerici D, Crocchiolo R, Vago L, Stanghellini MT, Noviello M, Messina C, Crotta A, Assanelli A, Marktel S, Olek S, Mastaglio S, Giglio F, Crucitti L, Lorusso A, Guggiari E, Lunghi F, Carrabba M, Tassara M, Battaglia M, Ferraro A, Carbone MR, Oliveira G, Roncarolo MG, Rossini S, Bernardi M, Corti C, Marcatti M, Patriarca F, Zecca M, Locatelli F, Bordignon C, Fleischhauer K, Bondanza A, Bonini C, Ciceri F.
Peccatori J, et al. Among authors: messina c.
Leukemia. 2015 Feb;29(2):396-405. doi: 10.1038/leu.2014.180. Epub 2014 Jun 4.
Leukemia. 2015.
PMID: 24897508
Clinical Trial.